Contract research and manufacturing organization (Biocon Group) providing drug discovery and CDMO services to global pharma/biotech.
Contract research and manufacturing organization (Biocon Group) providing drug discovery and CDMO services to global pharma/biotech.
Is paid by contract: some clients buy scientists' time by the hour or project, others lease dedicated labs and teams for several years, which makes revenue steadier. Large pharma partners such as Bristol Myers Squibb and Amgen have dedicated research centres there. Biocon, founded by Kiran Mazumdar-Shaw, is the majority shareholder.
In one line: India's smaller WuXi AppTec/Lonza peer for pharma CRO/CDMO services.
Moat: narrow (process know-how, customer qualification, regulatory licence). Biocon Group backing plus dedicated, long-term R&D partnerships with major global pharma clients.
Headquarters: Bengaluru, India · Founded: 1993 · Employees: 8,376
Size Syngene International (SYNGENE.NS) is an India Industrials company (Miscellaneous Commercial Services) with a market value of $1.88B, the 395th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹434.80 on 18 Nov 2026.
Performance Over six months the shares fell 7.8%, against -1.2% for the median peer and +3.8% for the India market (cap-weighted) — 9th lowest of 21 in its peer set.
Growth Revenue fell 6.0% over the last twelve months (peer median +20.5%); the operating margin is 13.0% (peer median 12.2%).
Valuation It trades at 70.7× forward earnings against a peer median of 20.4× (3rd most expensive of 16).
Price implies For today's price to make sense, revenue must grow about 36% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is +25 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 8.2 points below its cost of capital (15.3% WACC).
Next results Next results expected around 28 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹35.2B | ₹37.4B | ₹36.4B | ₹34.9B | ₹31.9B |
| Revenue growth | — | +3% | +4% | +9% | — |
| Gross profit | ₹11.4B | ₹9.84B | ₹10.2B | ₹10.3B | ₹9.36B |
| EBITDA | ₹9.07B | ₹9.97B | ₹10.5B | ₹10.8B | ₹9.94B |
| Net income | ₹1.86B | ₹3.17B | ₹4.96B | ₹5.10B | ₹4.64B |
| Free cash flow | n/a | ₹6.11B | ₹4.44B | ₹6.03B | ₹3.36B |
| Capital expenditure | n/a | ₹3.68B | ₹7.70B | ₹5.11B | ₹5.18B |
| Total debt | ₹5.07B | ₹4.58B | ₹5.78B | ₹5.55B | ₹8.15B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Syngene International SYNGENE.NS | $1.88B | -8% | -6% | 13% | 70.7× | 36.4% |
| SAI Life Sciences SAILIFE.NS | $4.07B | +59% | +16% | 22% | 87.2× | n/a |
| Divi's Laboratories DIVISLAB.NS | $31.3B | +60% | +22% | 34% | 73.5× | 47.1% |
| Wuxi Apptec 2359.HK | $64.1B | +51% | +38% | 44% | 19.5× | 8.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SYNGENE.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +9.4% | -0.1% | 5th highest of 21 |
| 6-month return | -7.8% | -1.2% | 9th lowest of 21 |
| Distance from 52-week high | -36.0% | -28.2% | 7th lowest of 21 |
| Revenue growth (TTM) | -6.0% | +20.5% | lowest of 19 |
| Operating margin | 13.0% | 12.2% | 10th highest of 20 |
| Forward P/E | 70.7× | 20.4× | 3rd most expensive of 16 |
| Growth the price implies (Req g, 7 yrs) | 36.4% | 17.7% | most demanding of 13 |
| Growth delivered (Del g) | +11.4% | +9.7% | 6th highest of 12 |
| Hurdle (Req g minus delivered) | +25.0 pp | -10.1 pp | 2nd most demanding of 12 |
| ROIC minus cost of capital | -8.2 pp | +1.8 pp | 4th lowest of 18 |
| EV / EBITDA | 19.3× | 13.9× | 4th most expensive of 11 |
| Net debt / EBITDA | -0.0× | 0.8× | 5th least indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Syngene International SYNGENE.NS | India | $1.88B | -8% | -6% | 13% | 70.7× | 36.4% | +11.4% |
| Jiangsu Guotai International 002091.SZ | China | $1.87B | -15% | +7% | 6% | 9.7× | -21.2% | +5.5% |
| Insperity NSP | United States | $1.86B | +55% | +2% | 0% | 19.6× | 19.4% | +9.7% |
| Prosegur Compania de Seguridad PSG.MC | Spain | $1.82B | +10% | +4% | 6% | 12.2× | -3.7% | +6.7% |
| Beijing Orient EcoEnergy 002310.SZ | China | $1.75B | -25% | +35% | 12% | n/a | 36.0% | -47.6% |
| Hoist Finance HOFI.ST | Sweden | $1.75B | +20% | +16% | 30% | 12.2× | n/a | n/a |
| Xi'an Taijin New Energy & Materials Sci-Tech 688813.SS | China | $1.73B | -42% | n/a | n/a | n/a | n/a | n/a |
| Firstsource Solutions FSL.NS | India | $2.04B | +13% | +20% | 12% | 20.4× | 19.2% | +13.5% |
| China Conch Venture 0586.HK | Hong Kong | $1.72B | -30% | +21% | 18% | 5.9× | n/a | n/a |
| International Gemological Institute IGIL.NS | India | $2.05B | +33% | +21% | 58% | 26.0× | 16.3% | +37.6% |
| Choice International CHOICEIN.NS | India | $1.70B | +8% | +34% | 27% | 47.6× | n/a | n/a |
| Suzhou Nanomicro Technology 688690.SS | China | $2.08B | -1% | +26% | 25% | 51.5× | 33.2% | +35.2% |
| Healthcare Services HCSG | United States | $1.69B | +21% | +4% | 6% | 21.3× | 4.3% | +0.9% |
| Biocytogen Pharmaceuticals (Beijing) 688796.SS | China | $2.09B | -33% | +40% | 24% | 73.0× | 31.0% | +41.1% |
| GRG Metrology & Test 002967.SZ | China | $1.68B | -20% | +13% | 13% | 22.2× | 3.6% | +14.4% |
| Sigurd Microelectronics 6257.TW | Taiwan | $2.10B | -28% | +18% | 24% | 11.3× | n/a | n/a |
| Wintech Nano (Suzhou) 688757.SS | China | $1.67B | -22% | +23% | 7% | n/a | n/a | n/a |
| TIC Solutions TIC | United States | $2.15B | +14% | +39% | -1% | n/a | 32.6% | n/a |
| Ipsos IPS.PA | France | $1.64B | -7% | +3% | 12% | 6.9× | -11.2% | +6.6% |
| Teemsun Technology 301571.SZ | China | $1.64B | -1% | +61% | 22% | n/a | n/a | n/a |
| Heron Neutron Medical 7799.TW | Taiwan | $2.15B | +56% | n/a | -5,319% | 355.2× | n/a | n/a |